PCSK9 and myocardial infarction: It was demonstrated that the cost-effectiveness of PCSK9 inhibition was improved in patients with a recent history of myocardial infarction and high LDL-C levels, which was consistent with the 2019 ESC/EAS guidelines and previous data.25